NasdaqCM:AXDX

Stock Analysis Report

Executive Summary

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Accelerate Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AXDX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-5.1%

AXDX

-1.2%

US Life Sciences

-1.3%

US Market


1 Year Return

-13.3%

AXDX

27.5%

US Life Sciences

22.0%

US Market

Return vs Industry: AXDX underperformed the US Life Sciences industry which returned 29.7% over the past year.

Return vs Market: AXDX underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

AXDXIndustryMarket
7 Day-5.1%-1.2%-1.3%
30 Day-3.4%2.2%1.6%
90 Day-1.1%14.2%8.9%
1 Year-13.3%-13.3%27.8%27.5%24.7%22.0%
3 Year-20.1%-20.1%105.0%103.6%49.4%39.7%
5 Year-23.7%-23.7%137.9%134.6%78.1%58.5%

Price Volatility Vs. Market

How volatile is Accelerate Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Accelerate Diagnostics undervalued compared to its fair value and its price relative to the market?

87.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AXDX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AXDX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AXDX is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: AXDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AXDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXDX is overvalued based on its PB Ratio (96.9x) compared to the US Life Sciences industry average (5.3x).


Next Steps

Future Growth

How is Accelerate Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

34.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AXDX's revenue (59.2% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: AXDX's revenue (59.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AXDX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Accelerate Diagnostics performed over the past 5 years?

-20.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXDX is currently unprofitable.

Growing Profit Margin: AXDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AXDX is unprofitable, and losses have increased over the past 5 years at a rate of -20% per year.

Accelerating Growth: Unable to compare AXDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXDX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.6%).


Return on Equity

High ROE: AXDX has a negative Return on Equity (-833.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Accelerate Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: AXDX's short term assets ($134.4M) exceed its short term liabilities ($6.1M).

Long Term Liabilities: AXDX's short term assets ($134.4M) exceed its long term liabilities ($130.9M).


Debt to Equity History and Analysis

Debt Level: AXDX's debt to equity ratio (1247%) is considered high.

Reducing Debt: AXDX's debt to equity ratio has increased from 0% to 1247% over the past 5 years.


Balance Sheet

Inventory Level: AXDX has a low level of unsold assets or inventory.

Debt Coverage by Assets: AXDX's debt is covered by short term assets (assets are 1.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AXDX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -8.8% each year.


Next Steps

Dividend

What is Accelerate Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage0.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AXDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AXDX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Accelerate Diagnostics's salary, the management and board of directors tenure and is there insider trading?

6.0yrs

Average management tenure


CEO

Larry Mehren (53yo)

7.6yrs

Tenure

US$716,331

Compensation

Mr. Lawrence Mehren, also known as Larry, has been the Chief Executive Officer, President and Director at Accelerate Diagnostics, Inc. since June 26, 2012, and its Interim Head of Europe, Middle East, and  ...


CEO Compensation Analysis

Compensation vs Market: Larry's total compensation ($USD716.33K) is below average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Larry's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.0yrs

Average Tenure

45yo

Average Age

Experienced Management: AXDX's management team is seasoned and experienced (6 years average tenure).


Board Age and Tenure

7.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: AXDX's board of directors are considered experienced (7.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Larry Mehren (53yo)

    President

    • Tenure: 7.6yrs
    • Compensation: US$716.33k
  • Steve Metzger (45yo)

    Head of Discovery

    • Tenure: 7.3yrs
  • Jack Phillips

    Chief Operating Officer

    • Tenure: 0.3yrs
  • Steve Reichling (41yo)

    Chief Financial Officer

    • Tenure: 7.3yrs
    • Compensation: US$691.69k
  • Ron Price (55yo)

    Senior VP & Head of Commercial Operations - Americas

    • Tenure: 4.8yrs
    • Compensation: US$349.23k
  • Constance Bridges

    Head of Regulatory & Quality

    • Tenure: 6yrs
  • Romney Humphries (38yo)

    Chief Scientific Officer

    • Tenure: 2.5yrs
  • Laura Pierson

    Investor Relations Officer


    Board Members

    • John Patience (71yo)

      Independent Chairman of the Board

      • Compensation: US$115.67k
    • Mark Miller (63yo)

      Independent Director

      • Tenure: 6.2yrs
      • Compensation: US$115.67k
    • Frank Ten Brink (62yo)

      Independent Director

      • Tenure: 6.8yrs
      • Compensation: US$115.67k
    • Tom Brown (71yo)

      Independent Director

      • Tenure: 2.8yrs
      • Compensation: US$115.67k
    • Jack Schuler (79yo)

      Independent Director

      • Tenure: 7.6yrs
      • Compensation: US$115.67k
    • Larry Mehren (53yo)

      President

      • Tenure: 7.6yrs
      • Compensation: US$716.33k
    • Matthew Strobeck (46yo)

      Independent Director

      • Tenure: 7.5yrs
      • Compensation: US$115.67k
    • Marin Kollef (62yo)

      Scientific Advisory Board Member

      • Connie Price

        Scientific Advisory Board Member

        • Richard Wunderink

          Scientific Advisory Board Member

          Company Information

          Accelerate Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


          Key Information

          • Name: Accelerate Diagnostics, Inc.
          • Ticker: AXDX
          • Exchange: NasdaqCM
          • Founded: 1982
          • Industry: Life Sciences Tools and Services
          • Sector: Pharmaceuticals & Biotech
          • Market Cap: US$896.724m
          • Shares outstanding: 54.64m
          • Website: https://acceleratediagnostics.com

          Number of Employees


          Location

          • Accelerate Diagnostics, Inc.
          • 3950 South Country Club Road
          • Suite 470
          • Tucson
          • Arizona
          • 85714
          • United States

          Listings

          TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
          AXDXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 1990
          0H8ELSE (London Stock Exchange)YesCommon StockGBUSDOct 1990
          AXDX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNOct 1990

          Biography

          Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona. 


          Company Analysis and Financial Data Status

          All financial data provided by Standard & Poor's Capital IQ.
          DataLast Updated (UTC time)
          Company Analysis2020/01/26 00:04
          End of Day Share Price2020/01/24 00:00
          Earnings2019/09/30
          Annual Earnings2018/12/31


          Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.